Efficacy of bladder-preserving therapy for patients with T3b, T4a, and T4b transitional cell carcinoma of the bladder

Jaewoo Cheon, Hyunchul Chung, Jaemann Song

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Radical cystectomy has been the most widely used method in the treatment of bladder cancer, but it is limited by major problems. Therefore, we investigated the results of bladder-preserving treatment in patients with T3b, T4a, and T4b transitional carcinoma of the bladder who underwent transurethral resection of bladder cancer and subsequent administration of chemotherapy. Materials and Methods: Of all patients who were diagnosed with bladder cancer and underwent bladder-preserving treatment between January 2001 and August 2008, 78 patients with at least 12 months of follow-up data were enrolled in this study. All patients received gemcitabine (1,000 mg/m2) and cisplatin (70 mg/m2) once per month postoperatively for a total of 6 months and completed a follow-up visit every 3 months. The patient survival rate and prognostic factors (age, tumor size, differentiation, number of lesions, stage, and presence of hydronephrosis) were assessed. The Kaplan-Meier method was used to analyze survival rate, and Cox multiple regression analysis was used for prognostic factors. Results: The mean patient age was 68.32±8.6 years, the mean duration of follow-up was 54.70±32.8 months, and the median duration of follow-up was 49.0 months. The 5-year survival rate was 66.2%. Single lesions were found in 28 cases (35.9%), and multiple lesions were found in 50 cases (64.1%). Stage T3b lesions were identified in 56 cases (71.8%), stage T4a lesions were identified in 16 cases (20.5%), and stage T4b lesions were identified in 6 cases (7.7%). Tumor size was less than 4 cm in 4 cases (59.0%) and greater than 4 cm in 32 (41.0%). Hydronephrosis was present in 21 cases (26.9%). In the 5-year survival analysis, prognostic factors significantly influencing survival rate were T-stage of the tumor and absence of hydronephrosis and complete regression after treatment (p<0.05). Multivariate analysis revealed that tumor stage and the absence of hydronephrosis were statistically significant prognostic indicators. Conclusions: In patients with T3b, T4a, and T4b transitional carcinoma of the bladder, bladder preservation may prevent a decrease in quality of life. Also, our findings suggest that this approach could be considered a primary treatment option for patients with T3b stage tumors without evidence of hydronephrosis.

Original languageEnglish
Pages (from-to)525-529
Number of pages5
JournalKorean Journal of Urology
Volume51
Issue number8
DOIs
Publication statusPublished - 2010 Aug 1

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder
Hydronephrosis
Urinary Bladder Neoplasms
Survival Rate
Therapeutics
Neoplasms
gemcitabine
Carcinoma
Cystectomy
Survival Analysis
Cisplatin
Multivariate Analysis
Regression Analysis
Quality of Life
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{b992f9293cbc4cf99a6145aafb97b11f,
title = "Efficacy of bladder-preserving therapy for patients with T3b, T4a, and T4b transitional cell carcinoma of the bladder",
abstract = "Purpose: Radical cystectomy has been the most widely used method in the treatment of bladder cancer, but it is limited by major problems. Therefore, we investigated the results of bladder-preserving treatment in patients with T3b, T4a, and T4b transitional carcinoma of the bladder who underwent transurethral resection of bladder cancer and subsequent administration of chemotherapy. Materials and Methods: Of all patients who were diagnosed with bladder cancer and underwent bladder-preserving treatment between January 2001 and August 2008, 78 patients with at least 12 months of follow-up data were enrolled in this study. All patients received gemcitabine (1,000 mg/m2) and cisplatin (70 mg/m2) once per month postoperatively for a total of 6 months and completed a follow-up visit every 3 months. The patient survival rate and prognostic factors (age, tumor size, differentiation, number of lesions, stage, and presence of hydronephrosis) were assessed. The Kaplan-Meier method was used to analyze survival rate, and Cox multiple regression analysis was used for prognostic factors. Results: The mean patient age was 68.32±8.6 years, the mean duration of follow-up was 54.70±32.8 months, and the median duration of follow-up was 49.0 months. The 5-year survival rate was 66.2{\%}. Single lesions were found in 28 cases (35.9{\%}), and multiple lesions were found in 50 cases (64.1{\%}). Stage T3b lesions were identified in 56 cases (71.8{\%}), stage T4a lesions were identified in 16 cases (20.5{\%}), and stage T4b lesions were identified in 6 cases (7.7{\%}). Tumor size was less than 4 cm in 4 cases (59.0{\%}) and greater than 4 cm in 32 (41.0{\%}). Hydronephrosis was present in 21 cases (26.9{\%}). In the 5-year survival analysis, prognostic factors significantly influencing survival rate were T-stage of the tumor and absence of hydronephrosis and complete regression after treatment (p<0.05). Multivariate analysis revealed that tumor stage and the absence of hydronephrosis were statistically significant prognostic indicators. Conclusions: In patients with T3b, T4a, and T4b transitional carcinoma of the bladder, bladder preservation may prevent a decrease in quality of life. Also, our findings suggest that this approach could be considered a primary treatment option for patients with T3b stage tumors without evidence of hydronephrosis.",
author = "Jaewoo Cheon and Hyunchul Chung and Jaemann Song",
year = "2010",
month = "8",
day = "1",
doi = "10.4111/kju.2010.51.8.525",
language = "English",
volume = "51",
pages = "525--529",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "8",

}

Efficacy of bladder-preserving therapy for patients with T3b, T4a, and T4b transitional cell carcinoma of the bladder. / Cheon, Jaewoo; Chung, Hyunchul; Song, Jaemann.

In: Korean Journal of Urology, Vol. 51, No. 8, 01.08.2010, p. 525-529.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of bladder-preserving therapy for patients with T3b, T4a, and T4b transitional cell carcinoma of the bladder

AU - Cheon, Jaewoo

AU - Chung, Hyunchul

AU - Song, Jaemann

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Purpose: Radical cystectomy has been the most widely used method in the treatment of bladder cancer, but it is limited by major problems. Therefore, we investigated the results of bladder-preserving treatment in patients with T3b, T4a, and T4b transitional carcinoma of the bladder who underwent transurethral resection of bladder cancer and subsequent administration of chemotherapy. Materials and Methods: Of all patients who were diagnosed with bladder cancer and underwent bladder-preserving treatment between January 2001 and August 2008, 78 patients with at least 12 months of follow-up data were enrolled in this study. All patients received gemcitabine (1,000 mg/m2) and cisplatin (70 mg/m2) once per month postoperatively for a total of 6 months and completed a follow-up visit every 3 months. The patient survival rate and prognostic factors (age, tumor size, differentiation, number of lesions, stage, and presence of hydronephrosis) were assessed. The Kaplan-Meier method was used to analyze survival rate, and Cox multiple regression analysis was used for prognostic factors. Results: The mean patient age was 68.32±8.6 years, the mean duration of follow-up was 54.70±32.8 months, and the median duration of follow-up was 49.0 months. The 5-year survival rate was 66.2%. Single lesions were found in 28 cases (35.9%), and multiple lesions were found in 50 cases (64.1%). Stage T3b lesions were identified in 56 cases (71.8%), stage T4a lesions were identified in 16 cases (20.5%), and stage T4b lesions were identified in 6 cases (7.7%). Tumor size was less than 4 cm in 4 cases (59.0%) and greater than 4 cm in 32 (41.0%). Hydronephrosis was present in 21 cases (26.9%). In the 5-year survival analysis, prognostic factors significantly influencing survival rate were T-stage of the tumor and absence of hydronephrosis and complete regression after treatment (p<0.05). Multivariate analysis revealed that tumor stage and the absence of hydronephrosis were statistically significant prognostic indicators. Conclusions: In patients with T3b, T4a, and T4b transitional carcinoma of the bladder, bladder preservation may prevent a decrease in quality of life. Also, our findings suggest that this approach could be considered a primary treatment option for patients with T3b stage tumors without evidence of hydronephrosis.

AB - Purpose: Radical cystectomy has been the most widely used method in the treatment of bladder cancer, but it is limited by major problems. Therefore, we investigated the results of bladder-preserving treatment in patients with T3b, T4a, and T4b transitional carcinoma of the bladder who underwent transurethral resection of bladder cancer and subsequent administration of chemotherapy. Materials and Methods: Of all patients who were diagnosed with bladder cancer and underwent bladder-preserving treatment between January 2001 and August 2008, 78 patients with at least 12 months of follow-up data were enrolled in this study. All patients received gemcitabine (1,000 mg/m2) and cisplatin (70 mg/m2) once per month postoperatively for a total of 6 months and completed a follow-up visit every 3 months. The patient survival rate and prognostic factors (age, tumor size, differentiation, number of lesions, stage, and presence of hydronephrosis) were assessed. The Kaplan-Meier method was used to analyze survival rate, and Cox multiple regression analysis was used for prognostic factors. Results: The mean patient age was 68.32±8.6 years, the mean duration of follow-up was 54.70±32.8 months, and the median duration of follow-up was 49.0 months. The 5-year survival rate was 66.2%. Single lesions were found in 28 cases (35.9%), and multiple lesions were found in 50 cases (64.1%). Stage T3b lesions were identified in 56 cases (71.8%), stage T4a lesions were identified in 16 cases (20.5%), and stage T4b lesions were identified in 6 cases (7.7%). Tumor size was less than 4 cm in 4 cases (59.0%) and greater than 4 cm in 32 (41.0%). Hydronephrosis was present in 21 cases (26.9%). In the 5-year survival analysis, prognostic factors significantly influencing survival rate were T-stage of the tumor and absence of hydronephrosis and complete regression after treatment (p<0.05). Multivariate analysis revealed that tumor stage and the absence of hydronephrosis were statistically significant prognostic indicators. Conclusions: In patients with T3b, T4a, and T4b transitional carcinoma of the bladder, bladder preservation may prevent a decrease in quality of life. Also, our findings suggest that this approach could be considered a primary treatment option for patients with T3b stage tumors without evidence of hydronephrosis.

UR - http://www.scopus.com/inward/record.url?scp=77955896706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955896706&partnerID=8YFLogxK

U2 - 10.4111/kju.2010.51.8.525

DO - 10.4111/kju.2010.51.8.525

M3 - Article

C2 - 20733957

AN - SCOPUS:77955896706

VL - 51

SP - 525

EP - 529

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 8

ER -